ClinicalTrials.gg
RecruitingNCT06600321Updated Nov 18, 2026

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

A Phase 1 interventional study of ALN-BCAT and Pembrolizumab in Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, sponsored by Alnylam Pharmaceuticals. Recruiting at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
158
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
134th of 775
158 · median 36
Started
2024
with 34 others
Phase 1
224 of 926
26 open now
Primary completion
2027-09
later than 131 of 244 live
Registered
850th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 134th largest by planned enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2024, is one of 224 in phase 1, reaches primary completion later than 131 of the 244 other live ones, and was the 850th registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma

Keywords

  • Hepatocellular carcinoma (HCC)
  • Pembrolizumab
  • CTNNB1
  • Liver disease
  • Liver cancer
  • Liver neoplasms
  • Carcinoma, hepatocellular
  • WNT pathway activating
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has HCC confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria
  • Has had at least one for unresectable advanced or disease
  • Has at least one wingless-related integration site (WNT)-pathway activating mutation
  • class A or B7

Exclusion criteria

Exclusion Criteria:

  • Has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors
  • Has symptomatic extrahepatic disease
  • Has received anti-cancer therapy or drugs ≤3 weeks prior to the first dose of study drug

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (estimated)

Study arms

  • Experimental
    Monotherapy: Dose Escalation

    Patients will be administered multiple doses of ALN-BCAT.

    Drug: ALN-BCAT

  • Experimental
    Monotherapy: Dose Expansion

    Patients will be administered multiple doses of ALN-BCAT.

    Drug: ALN-BCAT

  • Experimental
    Combination Therapy: Dose Escalation

    Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab.

    Drug: ALN-BCAT · Drug: Pembrolizumab

  • Experimental
    Combination Therapy: Dose Expansion

    Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab.

    Drug: ALN-BCAT · Drug: Pembrolizumab

Interventions

  • DrugALN-BCAT

    Administered by intravenous (IV) infusion

  • Administered by intravenous (IV) infusion

    Also known as: Keytruda, MK-3475

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs)

    Time frame: From the time of first dose of study drug administration to 30-37 days after the last dose

  2. Severity of AEs

    Time frame: From the time of first dose of study drug administration to 30-37 days after the last dose

  3. Dose Escalation: Occurrence of Dose-limiting Toxicities (DLTs)

    Time frame: From the time of first dose of study drug administration up to 21 days

  4. Dose Expansion: Antitumor Activity as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Up to 30-37 Days after the last dose

Secondary outcomes

  1. Concentrations of ALN-BCAT in Plasma

    Area Under the Plasma Concentration-time Curve (AUC), Maximum Observed Plasma Concentration (Cmax) Time to Maximum Plasma Concentration (Tmax)

    Time frame: Up to the end of the last study drug administration

  2. Percent Change in Gene that Encodes ß-catenin Protein (CTNNB1) Messenger Ribonucleic Acid (mRNA) Expression Comparing Pre- treatment with On-treatment Tumor Samples

    Time frame: Up to 30 days

  3. Dose Escalation: Antitumor Activity as assessed by RECIST v1.1

    Time frame: Up to 30-37 Days after the last dose

07

Study locations

22 of 23 sites recruiting
  • Clinical Trial Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Clinical Trial Site
    La Jolla, California 92037, United States
    Recruiting
  • Clinical Trial Site
    Los Angeles, California 90033, United States
    Recruiting
  • Clinical Trial Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Clinical Trial Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Clinical Trial Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Clinical Trial Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Clinical Trial Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Clinical Trial Site
    New York, New York 10029, United States
    Recruiting
  • Clinical Trial Site
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Trial Site
    Cleveland, Ohio 44106, United States
    Recruiting
  • Clinical Trial Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Clinical Trial Site
    Dallas, Texas 75390, United States
    Recruiting
  • Clinical Trial Site
    Houston, Texas 77030, United States
    Recruiting
  • Clinical Trial Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Trial Site
    Richmond, Virginia 23298, United States
    Recruiting
  • Clinical Trial Site
    Milan, 20132, Italy
    Recruiting
  • Clinical Trial Site
    Rozzano, 20089, Italy
    Recruiting
  • Clinical Trial Site
    Verona, 37134, Italy
    Recruiting
  • Clinical Trial Site
    Busan, 49241, South Korea
    Recruiting
  • Clinical Trial Site
    Seongnam, 13496, South Korea
    Recruiting
  • Clinical Trial Site
    Seongnam, 13620, South Korea
    Recruiting
  • Clinical Trial Site
    Seoul, 03722, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 33 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 33 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
2 updates, last Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 27, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06600321
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 30, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion